1 min read
Add as a preferred source on GoogleXenon Plans Q1 2027 Azetukalner Study With $1.2 Billion in Cash and Securities
Xenon submitted a new drug application for focal seizures in Q3 2026; topline results from X-NOVA2 are expected in December.
Xenon Pharmaceuticals plans to begin a Phase 3b/4 study of azetukalner in Q1 2027 as it pursues U.S. approval for focal seizures after filing a new drug application in Q3 2026.
Xenon ended Q3 with $1.2 billion in cash, cash equivalents and marketable securities. The company expects those resources to fund operations into 2029 under current plans.
Xenon expects topline results from X-NOVA2, a study in major depressive disorder (MDD), in December 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.